Vanguard Group Inc. Sells 61,420 Shares of Merit Medical Systems, Inc. $MMSI

Key Points

• Vanguard Group trimmed its stake in Merit Medical Systems by 0.9%, selling 61,420 shares and leaving it with 6,582,018 shares (about 11.10% of the company) valued at roughly $580.14 million.
• Several analysts have cut price targets recently (including JPMorgan, Needham, Piper Sandler and Wells Fargo), but the consensus remains a Moderate Buy with an average target of $92.80 and eight Buys versus three Holds.
• Merit beat Q1 estimates with $0.94 EPS (vs. $0.84 expected) and $381.88M revenue (vs. $377.59M expected), and issued FY2026 guidance of $4.01–$4.15 per share compared with analyst expectations of $3.61.

Vanguard Group Inc. cut its position in Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) by 0.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,582,018 shares of the medical instruments supplier's stock after selling 61,420 shares during the quarter. Vanguard Group Inc. owned approximately 11.10% of Merit Medical Systems worth $580,139,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of MMSI. Maseco LLP acquired a new position in Merit Medical Systems in the 4th quarter valued at $26,000. Salomon & Ludwin LLC acquired a new position in Merit Medical Systems in the 3rd quarter valued at $37,000. Danske Bank A S acquired a new position in Merit Medical Systems in the 3rd quarter valued at $42,000. Quarry LP grew its stake in Merit Medical Systems by 185.9% in the 3rd quarter. Quarry LP now owns 526 shares of the medical instruments supplier's stock valued at $44,000 after buying an additional 342 shares during the last quarter. Finally, First Horizon Corp acquired a new position in Merit Medical Systems in the 3rd quarter valued at $78,000. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on MMSI shares. JPMorgan Chase & Co. lowered their target price on shares of Merit Medical Systems from $95.00 to $77.00 and set an "overweight" rating on the stock in a research note on Friday. Citigroup reiterated an "outperform" rating on shares of Merit Medical Systems in a research note on Monday, April 20th. Needham & Company LLC lowered their target price on shares of Merit Medical Systems from $101.00 to $90.00 and set a "buy" rating on the stock in a research note on Friday. Piper Sandler lowered their target price on shares of Merit Medical Systems from $106.00 to $96.00 and set an "overweight" rating on the stock in a research note on Friday, April 17th. Finally, Wells Fargo & Company reduced their price target on shares of Merit Medical Systems from $78.00 to $74.00 and set an "equal weight" rating for the company in a report on Friday. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $92.80.

Merit Medical Systems Price Performance

Shares of Merit Medical Systems stock opened at $62.01 on Tuesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 5.08 and a quick ratio of 3.46. Merit Medical Systems, Inc. has a fifty-two week low of $60.79 and a fifty-two week high of $100.19. The firm has a fifty day moving average price of $70.68 and a two-hundred day moving average price of $79.78. The company has a market cap of $3.70 billion, a PE ratio of 26.84, a price-to-earnings-growth ratio of 1.75 and a beta of 0.58.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 earnings per share for the quarter, beating analysts' consensus estimates of $0.84 by $0.10. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. The firm had revenue of $381.88 million during the quarter, compared to the consensus estimate of $377.59 million. During the same period in the prior year, the firm earned $0.86 EPS. The business's revenue was up 7.4% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. Analysts expect that Merit Medical Systems, Inc. will post 3.61 EPS for the current year.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company's product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.

Want to see what other hedge funds are holding MMSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.